Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

cerivastatin (BAYCOL)


Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion.

More on Overprescribing Statins
March 2015
The most recently issued prescribing guidelines for cholesterol-lowering statin drugs were partly based on a new patient risk calculator that significantly overestimates patients’ risk of developing cardiovascular disease. Learn how this overestimation will lead to overprescribing of statin drugs to patients who will not benefit from using them.
Update on Withdrawals of Dangerous Drugs in the U.S.
January 2011
This article lists 11 of the prescription drugs that we warned Worst Pills, Best Pills News subscribers not to use before they were banned by the FDA. Subscribers knew an average of 3.3 years before the FDA acted that these medications were unsafe to use.
Pitavastatin (LIVALO): 8th Cholesterol-Lowering Statin Marketed in the U.S.
December 2010
Find out why you should not use the newest entry into the crowded statin market.
Grapefruit Juice and Drug Interactions
June 2002
Grapefruit juice can interact with a number of therapeutically important drugs that could lead to the possibility of toxicity. These drugs are listed in the article.
FDA Safety Office Recommends Warning About Liver Failure With The Cholesterol Lowering “Statin” Drugs
January 2001
The Food and Drug Administration’s (FDA) Office of Postmarketing Drug Risk Assessment (OPDRA) recommended in a memorandum dated May 1, 2000, that liver failure be included as an adverse reaction in the professional product labeling, or “package insert” for the family of cholesterol-lowering drugs known as “statins.” The statins now being marketed in the U.S. are .....


Search results below include Additional Information from Public Citizen where your selected drug is a primary subject of discussion.

Statin-associated rhabdomyolysis (HRG Publication #1733)
Letter to the editor that appeared in the April 2005 issue of Pharmacoepidemiology and Drug Safety. Submitted by Amer Ardati MD, Paul Stolley MD, Deanne E. Knapp PhD, Sidney M. Wolfe MD and Peter Lurie MD, MPH*